12 May 2026
HKSTP and PhIRDA Sign MoU to Support Mainland Biopharma Going Global via Hong Kong
Co‑building an International Hub for Life and Health Technology Innovation
Photo 1: HKSTP and PhIRDA today signed a memorandum of understanding at Hong Kong Science Park. Witnessed by Dr Ming Ge, Commissioner for Industry (Innovation and Technology) of the Innovation, Technology and Industry Bureau (back row, centre), Mr Terry Wong, CEO of HKSTP (back row, left), and Ms Feng Lan, Vice President of PhIRDA (back row, right), the memorandum was signed by Mr Eric Or, Chief Ecosystem Development Officer at HKSTP (front row, left), and Ms Lu Xiaoti, Deputy Secretary‑General of PhIRDA (front row, right), on behalf of both parties, marking the official launch of their joint effort to help Mainland innovative medicines expand onto the global stage.
Photo 2: Witnessed by Dr Ming Ge, Commissioner for Industry (Innovation and Technology) of the Innovation, Technology and Industry Bureau (back row, centre); Mr Terry Wong, CEO of HKSTP (back row, fifth from left); Ms Feng Lan, Vice President of PhIRDA (back row, fifth from right); Mr Andy Wong, Head of Innovation & Technology and Life & Health Sciences, Invest Hong Kong (back row, fourth from left); Dr Lu Xianping, Founder, Chairman and President of Shenzhen Chipscreen Biosciences Co., Ltd. (back row, fourth from right); Ms Vicky Tse, Head of Life and Health Technology at HKSTP (back row, third from left); Dr James Xue, Founder, Chairman and Chief Executive Officer of CANbridge Pharmaceuticals (back row, third from right); Dr Weng‑Li Yoon, Associate Director, Life and Health Technology (Therapeutics), HKSTP (back row, second from left); Mr Guo Tong, Chief Executive Officer, Clinical Research Centre, GoBroad Healthcare Group (back row, second from right); Dr Rose Cheng, Senior Manager, Therapeutics, Life and Health Technology, HKSTP (back row, first from left); and Mr Xiaoxin Chen, Chairman and Chief Executive Officer of Guangdong Raynovent Biotech Co. (back row, first from right), the memorandum of understanding was signed by Mr Eric Or, Chief Ecosystem Development Officer at HKSTP (front row, left), and Ms Lu Xiaoti, Deputy Secretary‑General of PhIRDA (front row, right), on behalf of both parties. Through the establishment of a structured collaboration platform, the two parties will connect the strengths and resources of Hong Kong, the Mainland and international markets, leverage Hong Kong’s unique advantage of being backed by the Motherland while connected to the world, and work together to advance Hong Kong’s development as an international hub for life and health technology.
Photo 3: HKSTP and PhIRDA signed a memorandum of understanding at Hong Kong Science Park. The signing was witnessed by distinguished guests including Dr Ming Ge, Commissioner for Industry (Innovation and Technology) of the Innovation, Technology and Industry Bureau (front row, centre), Mr Terry Wong, CEO of HKSTP (front row, fifth from right), and Ms Feng Lan, Vice President of PhIRDA (front row, fifth from left). The event brought together government officials, industry representatives and innovation ecosystem partners to support Mainland innovative pharmaceutical companies in using Hong Kong as a strategic gateway to accelerate alignment with global clinical research and international markets.
Photo 4: Mr Terry Wong, CEO of HKSTP (third from right), Ms Feng Lan, Vice President of PhIRDA (centre), and representatives from three PhIRDA member companies already established at Hong Kong Science Park took part in a media briefing to share their objectives and expectations for this collaboration.
Photo 5: Representatives from three PhIRDA member companies already established at Hong Kong Science Park took part in a media briefing to share how they are making full use of Hong Kong’s clinical and research resources to advance translational R&D for innovative medicines and their global expansion strategies.
(From left to right) Ms Meng Yu, Chief Operating Officer of HighTide Therapeutics; Mr Fei Cao, Co‑founder, President and Chief Financial Officer of InxMed (Hong Kong); and Mr Gaobo Zhou, Chief Investment Officer of Simcere Pharmaceutical.
(From left to right) Ms Meng Yu, Chief Operating Officer of HighTide Therapeutics; Mr Fei Cao, Co‑founder, President and Chief Financial Officer of InxMed (Hong Kong); and Mr Gaobo Zhou, Chief Investment Officer of Simcere Pharmaceutical.